Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target decreased by UBS Group from $5.00 to $2.20 in a research report released on Tuesday,Benzinga reports. UBS Group currently has a neutral rating on the stock.
ZNTL has been the topic of a number of other research reports. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Finally, Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.24.
Get Our Latest Analysis on ZNTL
Zentalis Pharmaceuticals Price Performance
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities research analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals in the third quarter worth $41,000. Capstone Investment Advisors LLC acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after purchasing an additional 5,333 shares during the last quarter.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Options Trading – Understanding Strike Price
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Following Congress Stock Trades
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.